Arcellx (ACLX) Cash from Financing Activities (2021 - 2025)
Arcellx (ACLX) recorded quarterly Cash from Financing Activities of $1.6 million in Q4 2025, down 98.1% quarter-over-quarter from $86.1 million in Q3 2025, and up 127.16% on a YoY basis from $719328.2 in Q4 2024.
Arcellx (ACLX) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Arcellx's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $1.6 million for Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 127.16% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $98.5 million (up 509.08% YoY), while the FY2025 annual figure was $98.5 million, up 509.08% from the prior year.
- Cash from Financing Activities was $1.6 million for Q4 2025 at Arcellx, down from $86.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $188.6 million in Q4 2023 to a low of -$10.4 million in Q2 2024.
- Historically, Cash from Financing Activities has averaged $36.2 million across 5 years, with a median of $928500.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 14252.44% in 2023, then slumped 9088.79% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $15000.0 in 2021, then surged by 8660.0% to $1.3 million in 2022, then soared by 14252.44% to $188.6 million in 2023, then sank by 103.19% to -$6.0 million in 2024, then surged by 127.16% to $1.6 million in 2025.
- The last three Cash from Financing Activities figures came in at $1.6 million (Q4 2025), $86.1 million (Q3 2025), and $10.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 1.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.63 Mn |
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | 86.10 Mn |
| Sep 30, 2025 | 86.10 Mn |
| Jun 30, 2025 | 10.26 Mn |
| Jun 30, 2025 | 10.26 Mn |
| Mar 31, 2025 | 543,000.00 |
| Mar 31, 2025 | 543,000.00 |
| Dec 31, 2024 | -6.02 Mn |
| Dec 31, 2024 | -6.02 Mn |
| Sep 30, 2024 | -4.66 Mn |
| Sep 30, 2024 | -4.66 Mn |
| Jun 30, 2024 | -10.43 Mn |
| Jun 30, 2024 | -10.43 Mn |
| Mar 31, 2024 | -2.99 Mn |
| Mar 31, 2024 | -2.99 Mn |
| Dec 31, 2023 | 188.59 Mn |
| Dec 31, 2023 | 188.59 Mn |
| Sep 30, 2023 | -4.99 Mn |
| Sep 30, 2023 | -4.99 Mn |